(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 January 2024 (18.01.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/013702 A2

(51) International Patent Classification:
A61K 35/17 (2015.01) *C12N 15/85* (2006.01)

(21) International Application Number:
PCT/IB2023/057202

(22) International Filing Date:
13 July 2023 (13.07.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/368,550 15 July 2022 (15.07.2022) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **JIANG, Jinlin**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **BOSCO, Emily**; c/o AstraZeneca Pharmaceuticals LP, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **GRIGORIADOU, Christina**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **GIARDINO TORCHIA, Maria Letizia**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **MOODY, Gordon**; c/o AstraZeneca Pharmaceuticals LP, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **BONDANZA, Attilio**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **CHU, Nina**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **REHFUSS, Patrick**; AstraZeneca Pharmaceuticals, Legal, IP, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: METHODS FOR EXPANDING T CELL POPULATIONS

(57) **Abstract:** Provided herein are methods for manufacturing, expanding, and/or generating genetically modified T cells comprising a chimeric antigen receptor (CAR) or T-cell receptor (TCR).

WO 2024/013702 A2